Seeking ethical designs for HIV clinical trials in treatment-experienced patients: An industry perspective

AIDS Research and Human Retroviruses

Volumn 22, Issue 11, 2006, Pages 1110-1112

  Mayers, Douglas L ^a   Chung, Jain ^b   Kohlbrenner, Veronika M ^a   Hall, David B ^a   DeMasi, Ralph A ^c   Neubacher, Dietmar ^a   Buss, Neil E ^d   Salgo, Miklos P ^b  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

^c Trimeris Inc   (United States)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ENFUVIRTIDE; LOPINAVIR PLUS RITONAVIR; TENOFOVIR; TIPRANAVIR;

ARTICLE; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG USE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONOTHERAPY; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PRIORITY JOURNAL; RESEARCH ETHICS; VIRUS LOAD;

ANTI-HIV AGENTS; CLINICAL TRIALS; DRUG INDUSTRY; HIV INFECTIONS; HUMANS; RESEARCH DESIGN;

EID: 33845428660     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.22.1110     Document Type: Article

References (13)

1. Lalezari JP, Henry K, O'Hearn M, et al.: Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175-2185.
2. Lazzarin A, Clotet B, Cooper D, et al.: Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003;348:2186-2195.
3. Cahn P for the RESIST-2 study team: 24-week data from RESIST-2: Phase 3 study of the efficacy and safety of either tipranavir/ritonavir (TPV/r) or an optimized ritonavir (RTV)-boosted standard-of-care (SOC) comparator PI (CPI) in a large randomised multicentre trial in treatment-experienced HIV+ patients. 7th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, November 14-18, 2004. Abstract PL14.3.
4. Hicks C for the RESIST-1 study team: RESIST-1: A phase 3, randomized, controlled, open-label, multicenter trial comparing tipranavir/ritonavir (TPV/r) to an optimized comparator protease inhibitor/r (CPI/r) regimen in antiretroviral (ARV) experienced patients: 24-week data. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, October 30-November 2, 2004. Abstract H-1137a.
5. Struble K, Murray J, Cheng B, Gegeny T, Miller V, and Gulick R: Antiretroviral therapies for treatment-experienced patients: Current status and research challenges. AIDS 2005;19:747-756.
6. De Gruttola V, Dix L, D'Aquila R, et al.: The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral Ther 2000;5:41-48.
7. McCallister S, Kohlbrenner V, Villacian J, Mukwaya G, Neubacher D, and Mayers D: 24-week combined analysis of the TPV RESIST studies of 1483 treatment-experienced patients given either tipranavir/ritonavir (TPV/r) or an optimized standard of care regimen using 1 of 4 RTV-boosted comparator PIs (CPI/r). HIV DART 2004, Montego Bay, Jamaica, December 12-16, 2004. Abstract 060.
8. Katlama C, Raffi F, Saag M, et al.: Week 12 response as a predictor of week 24,48 and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the TORO studies. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, October 30-November 2, 2004. Poster H-583.
9. Huson L, Chung J, and Salgo M: Comparison of methods of missing-data imputation in analysis of two Phase III trials treating HIV-1 infection. 2004 Joint Statistical Meetings, Toronto, Canada, August 8-12, 2004. Abstract 156.
10. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents: Department of Health and Human Services (DHHS). (Accessed October 10, 2005, at http://aidsinfo.nih.gov/ guidelines.)
11. Eron J, Benoit S, Jemsek J, et al.: Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 1995;333:1662-1669.
12. Gulick R, Mellors J, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-739.
13. Montaner J, Chung J, Guimaraes D, DeMasi R, Gafoor Z, and Salgo M: A treatment staging proposal derived from a post-hoc analysis of the 48 week results from the TORO studies. XV International AIDS Conference, Bangkok, Thailand, July 11-16, 2004. Abstract TuPeB4483.